# Dolby Laboratories, Inc.: financial statements, quarterly

DLB · NYSE · CIK 1308547 · [Financials](/sectors/financials.md) · fiscal year ends Sep 27

Pages: [Overview](/companies/dlb.md) · [Financials](/companies/dlb/financials.md) · [Filings](/companies/dlb/filings.md) · [Insiders](/companies/dlb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dlb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q4 FY2024 (2024-09-27) | Q1 FY2025 (2024-12-27) | Q2 FY2025 (2025-03-28) | Q3 FY2025 (2025-06-27) | Q4 FY2025 (2025-09-26) | Q1 FY2026 (2025-12-26) | Q2 FY2026 (2026-03-27) | Q3 FY2026 (2026-06-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [291 d](/filings/0001308547-25-000007.md) | [316](/filings/0001628280-25-003175.md) | [365](/filings/0001628280-25-021591.md) | [289](/filings/0001628280-25-037059.md) | [305 d](/filings/0001308547-25-000007.md) | [357](/filings/0001308547-26-000005.md) | [370](/filings/0001308547-26-000010.md) | [316](/filings/0001308547-26-000013.md) | [307 d](/filings/0001308547-25-000007.md) | [347](/filings/0001308547-26-000005.md) | [396](/filings/0001308547-26-000010.md) | [305](/filings/0001308547-26-000013.md) |
| Cost of revenue | $m | [35.6 d](/filings/0001308547-25-000007.md) | [32.1](/filings/0001628280-25-003175.md) | [38.8](/filings/0001628280-25-021591.md) | [35.7](/filings/0001628280-25-037059.md) | [34.0 d](/filings/0001308547-25-000007.md) | [40.8](/filings/0001308547-26-000005.md) | [35.8](/filings/0001308547-26-000010.md) | [44.0](/filings/0001308547-26-000013.md) | [39.5 d](/filings/0001308547-25-000007.md) | [43.2](/filings/0001308547-26-000005.md) | [44.7](/filings/0001308547-26-000010.md) | [40.3](/filings/0001308547-26-000013.md) |
| Gross profit | $m | [255 d](/filings/0001308547-25-000007.md) | [284](/filings/0001628280-25-003175.md) | [326](/filings/0001628280-25-021591.md) | [253](/filings/0001628280-25-037059.md) | [271 d](/filings/0001308547-25-000007.md) | [316](/filings/0001308547-26-000005.md) | [334](/filings/0001308547-26-000010.md) | [272](/filings/0001308547-26-000013.md) | [268 d](/filings/0001308547-25-000007.md) | [303](/filings/0001308547-26-000005.md) | [351](/filings/0001308547-26-000010.md) | [265](/filings/0001308547-26-000013.md) |
| Research and development | $m | [70.4 d](/filings/0001308547-25-000007.md) | [67.0](/filings/0001628280-25-003175.md) | [62.5](/filings/0001628280-25-021591.md) | [65.5](/filings/0001628280-25-037059.md) | [68.6 d](/filings/0001308547-25-000007.md) | [66.6](/filings/0001308547-26-000005.md) | [61.7](/filings/0001308547-26-000010.md) | [66.0](/filings/0001308547-26-000013.md) | [67.5 d](/filings/0001308547-25-000007.md) | [69.1](/filings/0001308547-26-000005.md) | [63.7](/filings/0001308547-26-000010.md) | [65.7](/filings/0001308547-26-000013.md) |
| Operating income | $m | [(3.5) d](/filings/0001308547-25-000007.md) | [66.2](/filings/0001628280-25-003175.md) | [109](/filings/0001628280-25-021591.md) | [36.8](/filings/0001628280-25-037059.md) | [46.4 d](/filings/0001308547-25-000007.md) | [79.9](/filings/0001308547-26-000005.md) | [108](/filings/0001308547-26-000010.md) | [47.6](/filings/0001308547-26-000013.md) | [29.7 d](/filings/0001308547-25-000007.md) | [62.2](/filings/0001308547-26-000005.md) | [113](/filings/0001308547-26-000010.md) | [34.3](/filings/0001308547-26-000013.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.9) d](/filings/0001308547-25-000007.md) | [13.3](/filings/0001628280-25-003175.md) | [23.5](/filings/0001628280-25-021591.md) | [10.5](/filings/0001628280-25-037059.md) | [0.9 d](/filings/0001308547-25-000007.md) | [18.0](/filings/0001308547-26-000005.md) | [28.0](/filings/0001308547-26-000010.md) | [9.0](/filings/0001308547-26-000013.md) | [(8.0) d](/filings/0001308547-25-000007.md) | [17.9](/filings/0001308547-26-000005.md) | [24.2](/filings/0001308547-26-000010.md) | [14.6](/filings/0001308547-26-000013.md) |
| Net income | $m | [9.2 d](/filings/0001308547-25-000007.md) | [67.0](/filings/0001628280-25-003175.md) | [97.8](/filings/0001628280-25-021591.md) | [38.4](/filings/0001628280-25-037059.md) | [58.6 d](/filings/0001308547-25-000007.md) | [67.8](/filings/0001308547-26-000005.md) | [91.8](/filings/0001308547-26-000010.md) | [46.1](/filings/0001308547-26-000013.md) | [49.3 d](/filings/0001308547-25-000007.md) | [53.3](/filings/0001308547-26-000005.md) | [94.9](/filings/0001308547-26-000010.md) | [28.6](/filings/0001308547-26-000013.md) |
| Diluted EPS | $ per share | not reported | [0.69](/filings/0001628280-25-003175.md) | [1.01](/filings/0001628280-25-021591.md) | [0.40](/filings/0001628280-25-037059.md) | not reported | [0.70](/filings/0001308547-26-000005.md) | [0.94](/filings/0001308547-26-000010.md) | [0.48](/filings/0001308547-26-000013.md) | not reported | [0.55](/filings/0001308547-26-000005.md) | [0.99](/filings/0001308547-26-000010.md) | [0.30](/filings/0001308547-26-000013.md) |
| Basic EPS | $ per share | not reported | [0.70](/filings/0001628280-25-003175.md) | [1.02](/filings/0001628280-25-021591.md) | [0.40](/filings/0001628280-25-037059.md) | not reported | [0.71](/filings/0001308547-26-000005.md) | [0.95](/filings/0001308547-26-000010.md) | [0.48](/filings/0001308547-26-000013.md) | not reported | [0.56](/filings/0001308547-26-000005.md) | [1.00](/filings/0001308547-26-000010.md) | [0.30](/filings/0001308547-26-000013.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | FY2024 (2024-09-27) | Q1 FY2025 (2024-12-27) | Q2 FY2025 (2025-03-28) | Q3 FY2025 (2025-06-27) | FY2025 (2025-09-26) | Q1 FY2026 (2025-12-26) | Q2 FY2026 (2026-03-27) | Q3 FY2026 (2026-06-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [745](/filings/0001628280-24-048519.md) | [657](/filings/0001628280-24-002964.md) | [710](/filings/0001628280-24-020061.md) | [742](/filings/0001628280-24-035707.md) | [482](/filings/0001308547-25-000007.md) | [521](/filings/0001628280-25-003175.md) | [627](/filings/0001628280-25-021591.md) | [699](/filings/0001628280-25-037059.md) | [702](/filings/0001308547-26-000013.md) | [644](/filings/0001308547-26-000005.md) | [594](/filings/0001308547-26-000010.md) | [669](/filings/0001308547-26-000013.md) |
| Current assets | $m | [1,488](/filings/0001628280-24-048519.md) | [1,451](/filings/0001628280-24-002964.md) | [1,552](/filings/0001628280-24-020061.md) | [1,469](/filings/0001628280-24-035707.md) | [1,194](/filings/0001308547-25-000007.md) | [1,286](/filings/0001628280-25-003175.md) | [1,389](/filings/0001628280-25-021591.md) | [1,338](/filings/0001628280-25-037059.md) | [1,388](/filings/0001308547-26-000013.md) | [1,408](/filings/0001308547-26-000005.md) | [1,415](/filings/0001308547-26-000010.md) | [1,326](/filings/0001308547-26-000013.md) |
| Total assets | $m | [2,980](/filings/0001628280-24-048519.md) | [2,936](/filings/0001628280-24-002964.md) | [3,045](/filings/0001628280-24-020061.md) | [2,974](/filings/0001628280-24-035707.md) | [3,110](/filings/0001308547-25-000007.md) | [3,159](/filings/0001628280-25-003175.md) | [3,229](/filings/0001628280-25-021591.md) | [3,196](/filings/0001628280-25-037059.md) | [3,228](/filings/0001308547-26-000013.md) | [3,192](/filings/0001308547-26-000005.md) | [3,249](/filings/0001308547-26-000010.md) | [3,157](/filings/0001308547-26-000013.md) |
| Current liabilities | $m | [422](/filings/0001628280-24-048519.md) | [394](/filings/0001628280-24-002964.md) | [443](/filings/0001628280-24-020061.md) | [355](/filings/0001628280-24-035707.md) | [418](/filings/0001308547-25-000007.md) | [442](/filings/0001628280-25-003175.md) | [457](/filings/0001628280-25-021591.md) | [389](/filings/0001628280-25-037059.md) | [438](/filings/0001308547-26-000013.md) | [444](/filings/0001308547-26-000005.md) | [475](/filings/0001308547-26-000010.md) | [416](/filings/0001308547-26-000013.md) |
| Total liabilities | $m | [608](/filings/0001628280-24-048519.md) | [573](/filings/0001628280-24-002964.md) | [607](/filings/0001628280-24-020061.md) | [526](/filings/0001628280-24-035707.md) | [623](/filings/0001308547-25-000007.md) | [642](/filings/0001628280-25-003175.md) | [646](/filings/0001628280-25-021591.md) | [582](/filings/0001628280-25-037059.md) | [596](/filings/0001308547-26-000013.md) | [589](/filings/0001308547-26-000005.md) | [622](/filings/0001308547-26-000010.md) | [564](/filings/0001308547-26-000013.md) |
| Shareholders' equity | $m | [2,355](/filings/0001628280-24-048519.md) | [2,346](/filings/0001628280-24-002964.md) | [2,421](/filings/0001628280-24-020061.md) | [2,433](/filings/0001628280-24-035707.md) | [2,477](/filings/0001308547-25-000007.md) | [2,508](/filings/0001628280-25-003175.md) | [2,574](/filings/0001628280-25-021591.md) | [2,605](/filings/0001628280-25-037059.md) | [2,623](/filings/0001308547-26-000013.md) | [2,594](/filings/0001308547-26-000005.md) | [2,618](/filings/0001308547-26-000010.md) | [2,584](/filings/0001308547-26-000013.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q4 FY2024 (2024-09-27) | Q1 FY2025 (2024-12-27) | Q2 FY2025 (2025-03-28) | Q3 FY2025 (2025-06-27) | Q4 FY2025 (2025-09-26) | Q1 FY2026 (2025-12-26) | Q2 FY2026 (2026-03-27) | Q3 FY2026 (2026-06-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [85.0 d](/filings/0001308547-25-000007.md) | [8.4](/filings/0001628280-25-003175.md) | [181 d](/filings/0001628280-25-021591.md) | [21.3 d](/filings/0001628280-25-037059.md) | [116 d](/filings/0001308547-25-000007.md) | [107](/filings/0001308547-26-000005.md) | [175 d](/filings/0001308547-26-000010.md) | [67.7 d](/filings/0001308547-26-000013.md) | [123 d](/filings/0001308547-25-000007.md) | [54.8](/filings/0001308547-26-000005.md) | [92.5 d](/filings/0001308547-26-000010.md) | [167 d](/filings/0001308547-26-000013.md) |
| Capital expenditure | $m | [8.2 d](/filings/0001308547-25-000007.md) | [6.1](/filings/0001628280-25-003175.md) | [8.9 d](/filings/0001628280-25-021591.md) | [7.6 d](/filings/0001628280-25-037059.md) | [7.4 d](/filings/0001308547-25-000007.md) | [6.8](/filings/0001308547-26-000005.md) | [6.9 d](/filings/0001308547-26-000010.md) | [6.4 d](/filings/0001308547-26-000013.md) | [16.2 d](/filings/0001308547-25-000007.md) | [4.6](/filings/0001308547-26-000005.md) | [9.1 d](/filings/0001308547-26-000010.md) | [15.0 d](/filings/0001308547-26-000013.md) |
| Dividends paid | $m | [25.8 d](/filings/0001308547-25-000007.md) | [28.6](/filings/0001628280-25-003175.md) | [28.7 d](/filings/0001628280-25-021591.md) | [28.7 d](/filings/0001628280-25-037059.md) | [28.6 d](/filings/0001308547-25-000007.md) | [31.5](/filings/0001308547-26-000005.md) | [31.8 d](/filings/0001308547-26-000010.md) | [31.6 d](/filings/0001308547-26-000013.md) | [31.6 d](/filings/0001308547-25-000007.md) | [34.3](/filings/0001308547-26-000005.md) | [34.3 d](/filings/0001308547-26-000010.md) | [34.0 d](/filings/0001308547-26-000013.md) |
| Share repurchases | $m | [25.0](/filings/0001628280-23-039389.md) | [80.0](/filings/0001628280-25-003175.md) | [25.0](/filings/0001628280-24-048519.md) | [35.0](/filings/0001628280-24-048519.md) | [20.0](/filings/0001628280-24-048519.md) | [15.0](/filings/0001308547-26-000005.md) | [35.0](/filings/0001308547-25-000007.md) | [70.0](/filings/0001308547-26-000005.md) | [35.0](/filings/0001308547-25-000007.md) | [70.0](/filings/0001308547-26-000013.md) | [65.0](/filings/0001308547-26-000013.md) | [65.0](/filings/0001308547-26-000013.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-30) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q1 FY2025 (2024-12-27) | Q2 FY2025 (2025-03-28) | Q3 FY2025 (2025-06-27) | Q1 FY2026 (2025-12-26) | Q2 FY2026 (2026-03-27) | Q3 FY2026 (2026-06-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [97.0](/filings/0001628280-24-002964.md) | [97.3](/filings/0001628280-24-020061.md) | [97.5](/filings/0001628280-24-035707.md) | [97.4](/filings/0001628280-25-003175.md) | [96.9](/filings/0001628280-25-021591.md) | [97.0](/filings/0001628280-25-037059.md) | [97.1](/filings/0001308547-26-000005.md) | [97.5](/filings/0001308547-26-000010.md) | [96.9](/filings/0001308547-26-000013.md) | [96.5](/filings/0001308547-26-000005.md) | [95.5](/filings/0001308547-26-000010.md) | [94.5](/filings/0001308547-26-000013.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.